Administration of anti-HER2 antibody after nonmyeloablative allogeneic stem cell transplantation in metastatic breast cancer.

Banna, G L; Aversa, S M L; Crivellari, G; Ghiotto, C; Chiarion-Sileni, V; Monfardini, S

Banna, G L; Aversa, S M L; Crivellari, G; Ghiotto, C; Chiarion-Sileni, V; Monfardini, S.

Br J Cancer ; 94(10): 1550-2, 2006 May 22.

Article in En | MEDLINE | ID: mdl-16641905

Subject(s)

Antibodies, Monoclonal/administration & dosage; Antibody-Dependent Cell Cytotoxicity/drug effects; Antineoplastic Agents/administration & dosage; Breast Neoplasms/immunology; Breast Neoplasms/therapy; Hematopoietic Stem Cell Transplantation; Receptor, ErbB-2/immunology; Adult; Antibodies, Monoclonal, Humanized; B-Lymphocytes/drug effects; Breast Neoplasms/secondary; Female; Graft vs Tumor Effect; Humans; Middle Aged; Receptor, ErbB-2/metabolism; T-Lymphocytes/drug effects; Trastuzumab

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Breast Neoplasms / Receptor, ErbB-2 / Hematopoietic Stem Cell Transplantation / Antibodies, Monoclonal / Antibody-Dependent Cell Cytotoxicity / Antineoplastic Agents Limits: Adult / Female / Humans / Middle aged Language: En Journal: Br J Cancer Year: 2006 Document type: Article Country of publication: United kingdom

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google